

the peer-review panel and NTP staff prior to the meeting.

Persons wishing to make oral comments, including those who originally registered to present comments at the October 7–8, 2013 and those now interested in making comments, are asked to register online at <http://ntp.niehs.nih.gov/go/38853> by December 5, 2013. As noted in the previous **Federal Register** notice (78 FR 51733), oral public comments may be presented in person or by teleconference line and will adhere to the procedures stated in that notice. The lines will be open from 8:30 a.m. until approximately 5:00 p.m. EST on December 12 and from 8:30 a.m. EST until adjournment on December 13, and oral comments will be received only during the formal public comment periods indicated on the preliminary agenda.

Dated: November 6, 2013.

John R. Bucher,

Associate Director, National Toxicology Program.

[FR Doc. 2013–26937 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Diversity R03 Applications in Digestive Diseases and Nutrition.

Date: December 16, 2013.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Thomas A. Tatham, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 760, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–3993, tathamt@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 5, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26900 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute on Aging Special Emphasis Panel, October 3, 2013, 1:00 p.m. to October 3, 2013, 3:00 p.m., DoubleTree by Hilton Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the **Federal Register** on September 10, 2013, 55265–55266 FR 175.

Meeting will be held November 20, 2013 from 12 p.m. to 3 p.m. at the National Institute on Aging, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892. The meeting is closed to the public.

Dated: November 4, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26907 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Evaluation of Trichloroethylene for the Report on Carcinogens; Request for Nominations of Scientific Experts for Proposed Webinar

SUMMARY: The National Toxicology Program (NTP) Office of the Report on Carcinogens (ORoC) requests nominations of speakers for a proposed webinar to obtain information related to evaluating the potential association of exposure to trichloroethylene (TCE) and cancer.

DATES: The deadline for receipt of nominations of speakers is December 9, 2013.

ADDRESSES: Information can be submitted electronically on the ORoC TCE Web page (<http://ntp.niehs.nih.gov/go/37899>) or to lunn@niehs.nih.gov.

FOR FURTHER INFORMATION CONTACT: Dr. Ruth Lunn, Director, ORoC, Division of the NTP, NIEHS, P.O. Box 12233, MD K2–14, Research Triangle Park, NC 27709. Phone: (919) 316–4637, FAX: (301) 480–2970, email: lunn@niehs.nih.gov. Hand Delivery/Courier: NIEHS, Room 2138, 530 Davis Drive, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION:

Information on Proposed Webinar: TCE is a candidate substance under evaluation for the Report on Carcinogens (RoC) (<http://ntp.niehs.nih.gov/go/37899>). Several comprehensive reviews have identified non-Hodgkin's lymphoma and cancer of the liver and kidney as sites of concern in humans, and the RoC evaluation will be limited to these outcomes.

As part of the evaluation, the ORoC proposes to convene a webinar to obtain input on scientific issues related to evaluating human epidemiologic studies of exposure to TCE and cancer risk and use this input to help inform its cancer evaluation of TCE. The webinar will include a series of presentations by invited speakers that address the quality of the methods used in the epidemiology studies to assess exposure to TCE and cancer outcome (primarily lymphohematopoietic cancer) and information on TCE exposure in the studies. Speakers on exposure and cancer-outcome classification will be asked to (1) identify the methods used to assess exposure or outcome, (2) discuss the validity and reliability of the methods used to classify exposure (such as job title, job exposure matrix, biomonitoring, and expert assessment) or cancer outcome (such as mortality or incidence data), and (3) examine how misclassification of exposure (either qualitative or quantitative) or cancer outcome would affect interpretation of the study's findings. The speaker addressing TCE exposure will be asked to compare measured or estimated levels of exposure to TCE and its prevalence in the epidemiologic studies and to discuss how these data may explain potential heterogeneity of findings across studies and inform the assessment for a specific type of cancer.

It is envisioned that the webinar will include time for questions to speakers by webinar attendees and open discussion. Once plans are finalized, the list of speakers and logistical details for

the webinar will be announced in the **Federal Register**.

Request for Nomination of Speakers: The OROc invites nominations of speakers for the webinar with expertise in exposure assessment, industrial hygiene, cancer epidemiology, or lymphohematopoietic cancers and knowledge of cancer studies on exposure to TCE. Self nomination is permitted. Each nomination should include (1) contact information for the nominee [name, affiliation (if any), address, telephone, and email], (2) a short description of the individual's expertise relative to topics covered above in "Information on Proposed Webinar," and (3) current curriculum vitae. Nominations of experts can be submitted on-line via the TCE candidate substance Web page (<http://ntp.niehs.nih.gov/go/37899>) or by email to lunn@niehs.nih.gov; receipt will be acknowledged by email. Persons submitting nominations on-line or by email should provide their name, contact information, affiliation, and sponsoring organization (if any). The deadline for nominations is December 9, 2013. Persons selected as speakers will be notified by email at least 30 days prior to the webinar.

Responses to this request for nominations are voluntary. This request for nominations is for planning purposes only. Please note that the U.S. Government will not pay for the preparation of any information submitted, and no proprietary, classified, confidential, or sensitive information should be included in the submission.

Background Information on TCE: TCE, a volatile chlorinated alkene used mainly as a metal cleaner and degreaser, has been listed in the RoC as *reasonably anticipated to be a human carcinogen* since 2000 (<http://ntp-server.niehs.nih.gov/ntp/roc/twelfth/profiles/Trichloroethylene.pdf>). The NTP selected TCE for evaluation to determine whether a change in its listing status in the RoC might be warranted because of the extensive database of recent cancer studies on TCE and the public health concern due to its pervasiveness in the environment and its presence in food, numerous consumer products, and the workplace. Additional information on the status of the RoC review of TCE is available at <http://ntp.niehs.nih.gov/go/37899>.

Background Information on the RoC: The RoC is a congressionally mandated, science-based, public health report that identifies agents, substances, mixtures, or exposures (collectively called "substances") in our environment that pose a cancer hazard for people in the

United States. The NTP prepares the RoC, on behalf of the Secretary of Health and Human Services, using a four-part process and established criteria (<http://ntp.niehs.nih.gov/go/rocprocess>). Published biennially, each edition of the RoC is cumulative and consists of substances newly reviewed in addition to those listed in previous editions. The 12th RoC, the latest edition, was published on June 10, 2011 (available at <http://ntp.niehs.nih.gov/go/roc12>). The 13th RoC is under development.

Dated: November 5, 2013.

John R. Bucher,

Associate Director, National Toxicology Program.

[FR Doc. 2013-26909 Filed 11-8-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, October 22, 2013, 08:00 a.m. to October 22, 2013, 04:00 p.m., Hotel Kabuki, 1625 Post Street, San Francisco, CA, 94115 which was published in the **Federal Register** on September 10, 2013, 78 FR 55266.

The meeting will be held on November 25, 2013, 08:00 a.m. to November 25, 2013, 04:00 p.m., National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD, 20892. The meeting is closed to the public.

Dated: November 5, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-26898 Filed 11-8-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Cancer Genetics Study Section, October 10, 2013, 08:00 a.m. to October 10, 2013, 06:30 p.m., Renaissance Arlington Capital View Hotel, 2800 South Potomac Ave,

Arlington, VA, 22202 which was published in the **Federal Register** on September 11, 2013, 78 FR 176 Pgs. 55752-55753.

The meeting will be held at the Embassy Suites Chevy Chase, 4300 Military Rd. NW., Washington, DC 20015. The meeting will start on January 10, 2014 at 8:00 a.m. and end January 10, 2014 at 6:00 p.m. The meeting is closed to the public.

Dated: November 5, 2013.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-26893 Filed 11-8-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; NIBIB P41 NMR Meeting (2014/05).

Date: March 13-14, 2014.

Time: 4:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Ruth Grossman, DDS, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Room 960, Bethesda, MD 20892, 301-496-8775, grossmanrs@mail.nih.gov.

Dated: November 5, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-26903 Filed 11-8-13; 8:45 am]

BILLING CODE 4140-01-P